{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 111,
  "pageCount": 415,
  "prevPage": 110,
  "nextPage": 112,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/111",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-111",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The KOL stated that these two cases of diabetes – on a relatively small trial size – are under-the-radar and seemed to hint at pressure to stay silent, perhaps from a patient association or Soleno",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29e-f04bf83db029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The KOL alleged that Soleno’s data shows a diabetes signal – “we did see the data, and we did see the number of people who had diabetes” – “I do know at least two families that dropped out of the Vykat study...both of their kids got diabetes...they were not pre-diabetic...that’s concerning to me...and both of them are still now struggling with controlling diabetes...people who take this this drug – you now have another problem that you have to treat, that’s a bigger problem.” The KOL stated that these two cases of diabetes – on a relatively small trial size – are under-the-radar and seemed to hint at pressure to stay silent, perhaps from a patient association or Soleno – “...and they’ve been told, like they’re pretty quiet about it...FYI, they don’t really feel comfortable telling other people about it because they don’t want to scare anybody.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d931314-5820-4b19-b696-f2fe7226a990",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "Two patients in their early 20's allegedly developed diabetes shortly after starting Vykat; still uncontrolled several years later; Q: “And you know this because you've spoken with the families?” A: “Mm-hmm. And they've been told, like they're pretty quiet about it. FYI, they don't feel really comfortable telling other people about it because they don't want to scare anybody. Just this idea that they feel uncomfortable in the community talking about it.” Q: “And were they obese — I get all these kids are at risk for diabetes.” A: “Sure. Just a little something. If you look at them on the street, they would not stand out as somebody who was obese. I would say slightly overweight for both of them.” – KOL in the PWS field; closely involved with Soleno's trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d3b1f1c-dc59-42c7-83f7-2beca374481d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“we did see the data, and we did see the number of people who had diabetes” — KOL in the PWS field; closely involved with Soleno’s trial",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29e-f740ea546d3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c0045b7-9642-4d8d-a633-3fdd1b641ed2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "daa7bd41-cf1c-4bcd-b7e9-495183e9ee82",
      "evidence": "The slide explicitly aims to expose a potential cover-up of adverse clinical trial events.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}